Tissue Response to Subcutaneous Infusion Catheter

Insulin infusion pump, continuous glucose monitoring (CGM), and insulin infusion set (IIS) have been developed to be increasingly feasible for people with type 1 diabetes (T1D). Several recently approved CGMs are transitioning from 7-day to 10-day wear time without the need for fingerprick recalibration. Nevertheless, studies and improvements on IIS, a critical part of insulin pump therapy, have been limited. In particular, the recommended wear time of IIS is still 2-3 days, which can hardly match the current duration of CGM for potential closed-loop system development. It is generally believed that both the inserted catheter and the subsequent infused insulin drug could induce particular subcutaneous tissue response and skin-related complications at the infusion site. In certain cases, poor glycaemic control, increased risk of hypoglycemia, and serious cosmetic impact on people with diabetes were observed. Skin complication has also been attributed as an important factor resulting users to discontinue insulin pump therapy. This article provides the rare systematic review of IIS induced subcutaneous tissue responses and skin complications, including the impacts from the inserted catheters, the subcutaneous infused insulin, and the adhesive or tape used to immobilize the catheter. The FDA’s recommendation for the frequency of IIS change was further discussed. Future studies on this topic are required to further understand the IIS-related problems, and future strategies could be developed accordingly to significantly reduce the incidence of these problems, extend the wear time, and increase the acceptance of insulin pump based therapy.

• Publication year

  2020

• Venue

  Journal of Diabetes Science and Technology

• Publication date

  2020-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1932296819837972PMID 30931603PMCID PMC7196874
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ionic liquids for oral insulin delivery

  2018cited by this paper
• Continuous glucose monitoring: a systematic review of sensor systems and prospects

  2018cited by this paper
• Coated glucose sensors dodge recalibration

  2018cited by this paper
• Reduction of measurement noise in a continuous glucose monitor by coating the sensor with a zwitterionic polymer

  2018cited by this paper
• Current and Emerging Technology for Continuous Glucose Monitoring

  2017cited by this paper
• Indian Injection Technique Study: Injecting Complications, Education, and the Health Care Professional

  2017cited by this paper
• Examination of the foreign body response to biomaterials by nonlinear intravital microscopy

  2016cited by this paper
• Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis

  2016cited by this paper
• Insulin Infusion Sets: A Critical Reappraisal

  2016cited by this paper
• Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers

  2016cited by this paper
• Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities

  2016cited by this paper
• Recent advances in liposome surface modification for oral drug delivery.

  2016cited by this paper
• New Insulin Delivery Recommendations.

  2016cited by this paper
• A Web-Based Study of the Relationship of Duration of Insulin Pump Infusion Set Use and Fasting Blood Glucose Level in Adults with Type 1 Diabetes

  2015cited by this paper
• Modeling the Physiological Factors Affecting Glucose Sensor Function in Vivo

  2015cited by this paper
• Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics

  2015cited by this paper
• Frequency of dermatological side effects of continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes.

  2015cited by this paper
• Non-genetic engineering of cells for drug delivery and cell-based therapy.

  2015cited by this paper
• Using Insulin Infusion Sets in CSII for Longer Than the Recommended Usage Time Leads to a High Risk for Adverse Events

  2015cited by this paper
• Cell based metabolic barriers to glucose diffusion: macrophages and continuous glucose monitoring.

  2014cited by this paper
• Continuous subcutaneous insulin infusion in preschool children: butt or tummy, which is the best infusion set site?

  2014cited by this paper
• Risk factors for discontinuation of insulin pump therapy in pediatric and young adult patients.

  2014influential reference
• Clinical Accuracy of a Continuous Glucose Monitoring System With an Advanced Algorithm

  2014cited by this paper
• Randomized Trial of Infusion Set Function: Steel Versus Teflon

  2014cited by this paper
• Nonmetabolic Complications of Continuous Subcutaneous Insulin Infusion: A Patient Survey

  2014cited by this paper
• Overview of insulin and non-insulin delivery devices in the treatment of diabetes.

  2014cited by this paper
• We Need More Research and Better Designs for Insulin Infusion Sets

  2014cited by this paper
• Type 1 diabetes.

  2014cited by this paper
• Injectable nano-network for glucose-mediated insulin delivery.

  2013cited by this paper
• A New-Generation Continuous Glucose Monitoring System: Improved Accuracy and Reliability Compared with a Previous-Generation System

  2013cited by this paper
• Insulin Infusion Set: The Achilles Heel of Continuous Subcutaneous Insulin Infusion

  2012influential reference
• Insulin-pump therapy for type 1 diabetes mellitus.

  2012cited by this paper
• Continuous glucose monitoring systems for type 1 diabetes mellitus.

  2012cited by this paper
• Metabolic Biofouling of Glucose Sensors in Vivo: Role of Tissue Microhemorrhages

  2011cited by this paper
• Continuous glucose monitoring

  2010cited by this paper
• Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis

  2010cited by this paper
• New injection recommendations for patients with diabetes.

  2010cited by this paper
• The Third Injection Technique Workshop in Athens (TITAN).

  2010cited by this paper
• Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion.

  2010cited by this paper
• Cochrane review: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus

  2010cited by this paper
• Pilot Study for Assessment of Optimal Frequency for Changing Catheters in Insulin Pump Therapy—Trouble Starts on Day 3

  2010influential reference
• Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.

  2010cited by this paper
• Effect of Steel and Teflon Infusion Catheters on Subcutaneous Adipose Tissue Blood Flow and Infusion Counter Pressure in Humans

  2009cited by this paper
• Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta‐analysis of randomized control trials

  2009cited by this paper
• Adhesion of pancreatic beta cells to biopolymer films

  2009cited by this paper
• Dermatological side effects and complications of continuous subcutaneous insulin infusion in preschool‐age and school‐age children

  2009influential reference
• Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy

  2009cited by this paper
• Continuous glucose monitoring and intensive treatment of type 1 diabetes.

  2008cited by this paper
• A Review of the Foreign-body Response to Subcutaneously-implanted Devices: The Role of Macrophages and Cytokines in Biofouling and Fibrosis

  2008cited by this paper
• A review of the foreign-body response to subcutaneously-implanted devices: the role of macrophages and cytokines in biofouling and fibrosis.

  2008cited by this paper
• Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents.

  2008influential reference
• Bacterial strains colonizing subcutaneous catheters of personal insulin pumps.

  2007cited by this paper
• Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans.

  2007cited by this paper
• Lipodystrophy Reactions to Insulin

  2007cited by this paper
• Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trial

  2006cited by this paper
• Impaired absorption of insulin aspart from lipohypertrophic injection sites.

  2005cited by this paper
• Patient management of long-term continuous subcutaneous insulin infusion.

  2005cited by this paper
• Skin-related complications of insulin therapy: epidemiology and emerging management strategies.

  2003cited by this paper
• Skin-Related Complications of Insulin Therapy

  2003influential reference
• A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications?

  2003cited by this paper
• Poor glycaemic control caused by insulin induced lipohypertrophy

  2003cited by this paper
• Sensitization to methyl methacrylate in the plastic catheter of an insulin pump infusion set

  2001cited by this paper
• Allergic contact dermatitis from phenoxyethoxy ethylacrylates in optical fiber coating, and glue in an insulin pump set

  2001cited by this paper
• Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy.

  2001cited by this paper
• Carriage of Staphylococcus aureus and Inflamed Infusion Sites With Insulin-Pump Therapy

  1989cited by this paper
• Cellulitis caused by Rhizomucor pusillus in a diabetic patient receiving continuous insulin infusion pump therapy.

  1989cited by this paper
• Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for Type 1 (insulin-dependent) diabetes mellitus: a one centre experience

  1989cited by this paper
• Factors Related to Discontinuation of Continuous Subcutaneous Insulin-Infusion Therapy

  1988cited by this paper
• Long-term metabolic control with insulin pump therapy. Report of experience with 127 patients.

  1985influential reference
• Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients.

  1984cited by this paper
• Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps.

  1984cited by this paper
• Toxic-shock syndrome in a patient using a continuous subcutaneous insulin infusion pump--Idaho.

  1983cited by this paper
• Guidelines for Prevention of Intravascular Infections

  1982cited by this paper

• On-body drug delivery systems: State-of-the-art technologies, clinical application, and future perspectives.

  2025cites this paper
• A Neglected Complication of Insulin Therapy Due to Errors in Injection Technique: Skin Lipohypertrophies: A Narrative Review

  2025cites this paper
• Development of a Real-time Force-based Algorithm for Infusion Failure Detection

  2024cites this paper
• Biomimetic polymers with phosphorylcholine groups as biomaterials for medical devices

  2024cites this paper
• The DERMIS Study: Methodologies, Results, and Implications for the Future.

  2024cites this paper
• Promising strategies for smart insulin delivery system: Glucose-sensitive microneedle.

  2024cites this paper
• Glucose‐Responsive Microneedle Patch With Variable Crosslinking Density and Flexible Core–Shell Structure for Insulin Delivery

  2023cites this paper
• The Future of Diabetes Therapies: New Insulins and Insulin Delivery Systems, Glucagon-Like Peptide 1 Analogs, and Sodium-Glucose Cotransporter Type 2 Inhibitors, and Beta Cell Replacement Therapy.

  2023cites this paper
• An injectable and biodegradable zwitterionic gel for extending the longevity and performance of insulin infusion catheters

  2023influential citation
• Recent advances in oral insulin delivery technologies.

  2023cites this paper
• Habits related to the use of insulin infusion set in patients with type 1 diabetes on pump therapy - the effect of the educational intervention.

  2022cites this paper
• Can a Mixture of Insulin and a Nonsteroidal Anti-inflammatory Drug Prolong Insulin Pump Catheter Wear Time in Adults With Type 1 Diabetes?

  2022cites this paper
• In Vivo Study of the Inflammatory Tissue Response Surrounding a Novel Extended-Wear Kink-Resistant Insulin Infusion Set Prototype Compared With a Commercial Control Over Two Weeks of Wear Time

  2022cites this paper
• Insulin Pump Related Inpatient Admissions in a National Sample of Youth with Type 1 diabetes.

  2022cites this paper
• Impact of Infusion Set Materials and Designs on the Subcutaneous Response in People With Diabetes: A Rapid Review of the Literature

  2022cites this paper
• The improved survival rate and cost-effectiveness of a 7-day continuous subcutaneous insulin infusion set

  2021cites this paper
• Leveraging Mechanical Forces to Target Insulin Injection–Induced Lipohypertrophy and Fibrosis

  2021cites this paper
• Basal Insulin degludec and GLycemic control ComparEd to Aspart via insulin Pump in type 1 diabetes (BIGLEAP): a single-center, open-label, randomized, crossover trial.

  2021cites this paper
• Preparation of phenylboronic acid‐based hydrogel microneedle patches for glucose‐dependent insulin delivery

  2021cites this paper